| 4765
LI et aL.
of IHCs, which in turn convert sound into electrical signals. 2 Approximately 95% of spiral ganglion neuron (SGNs) are type I SGNs, which can be further subdivided into three subtypes: Type I-A, Type I-B, and Type I-C, and the remaining 5% of SGNs are type II SGNs, as supported by both morphological and single-cell transcriptome analysis. [3] [4] [5] [6] IHCs are the primary sensory cells that are connected to myelinated type I SGNs, while OHCs are innervated by unmyelinated type II SGNs. The primary role of type I SGNs is to transmit sound-induced electrical signals from IHCs to the cochlear nucleus located in the brainstem; in contrast type II SGNs are involved in the reflexive medial olivocochlear suppression of cochlear amplification. 7 Degeneration of SGNs can occur as a direct consequence of exposure to large sounds, infection or aging, to name only a few causes, or as a secondary effect of damaging auditory HCs which provide neurotrophic support to SGNs. 8 Degeneration of SGNs causes permanent hearing impairment as they have no intrinsic regenerative capacity. 9 Understanding how to preserve and/or regenerate SGNs is of growing clinical importance as the demand for cochlear implant or hearing aids is increasing with the aging population and their success critically depends on having functional SGNs cells to relay auditory information to the brain. In the case of partial damage to SGNs, ectopic neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) can protect the remaining cells. 10 In the case of severe loss of SGNs, cell transplantation of otic neuroprogenitors derived from human embryonic stem cells can partially rescue deafness in the ouabain-mediated neuropathic gerbil model. 11, 12 However, transplanting stem/progenitor cells into adult cochlea is technically challenging and is accompanied by the risk of tumor formation. 13 An alternative solution is in situ regeneration, which involves reprogramming cochlear glial cells, which surround SGNs, into neuronal lineages. A similar approach has been successful in regenerating neurons from glial cells in the mouse cortex. 14 Recently, isolated cochlear glial cells were converted in vitro into SGNs via the induction of Ascl1 and/or Neurod1. 15 Nonetheless, it remains unknown whether this is possible in vivo.
We addressed this question by inducing ectopic Neurog1 (Ngn1) and Neurod1 in neonatal cochlear glial cells in vivo. Our lineage tracing analysis showed that neonatal glial cells started to express the SGN markers, Tuj1, Map2, and Prox1, as early as 6 days after expressing Ngn1 and Neurod1; we defined these cells as "glial cell-derived new SGNs" or "new SGNs" for short. We found that not all neonatal glia cells with Ngn1 and Neurod1 expression became new SGNs, consistent with previous glial cells to neuron conversion studies in retina. 16, 17 Promisingly, the new SGNs also decreased expression of glial genes and could survive at least until 6 weeks of age. More importantly, a smaller subset of new SGNs expressed Mafb, Gata3, and other SGN genes and displayed large rounded somas similar to that of wild-type SGNs. Our transcriptomic analysis showed that Mafb+/Gata3+ new SGNs resembled type I SGNs and that in general two copies of Ngn1 and Neurod1 resulted in higher efficiency of cellular reprogramming.
| MATERIALS AND METHODS

| Animals
The Rosa26-LSL-Ngn1-Neurod1/+ mouse was generated by CRISPR/Cas9-mediated gene targeting in mouse zygotes. The sequence used (without PAM) for the sgRNA in Rosa26 locus ( Figure 1A) was: 5′-AAGGCCGCACCCTTCTCCGG-3′. The cDNA sequences of Ngn1 (gene ID: 18014) and Neurod1 (gene ID: 18012) used were identical to ENSMUST00000058475.5 and ENSMUST00000041099.4, respectively, on the ensembl website (www.ensem bl.org). Donor vector DNA ( Figure 1B) together with Cas9 and sgRNA were injected into C57BL/6 mouse zygotes. Detailed donor DNA sequences are available upon request. Founder F0 mice were mosaic and screened by junction PCR. The positive F0 mice were crossed with wild-type C57BL/6 mice for germline transition and generating stable F1 mice. F1 mice derived from positive F0 founders were further screened by junction PCR and southern blot analysis ( Figure 1D ,E). The southern blot confirmed that there was no random insertion of donor DNA in the mice's genomes. Southern blot was performed according to our previously described protocol. 2 For routine genotype analysis of F2 or later mouse progeny, PCR was performed on mouse tail DNA with the following three primers (used simultaneously) ( Figure 1 ): F1: 5′-AGTCGCTCTGAGTTGTTATCAG-3′; R1: 5-AGTC CCTATTGGCGTTACTATGG-3′; R2: 5′-TGAGCATGTCT TTAATCTACCTCGATG-3′. The PCR amplicon derived from primer F1 and R2 in wild type was 469 bp and 7464 bp in knock-in (KI) allele. 7464 bp was too long to be amplified using our PCR protocol. PCR amplicon of primer F1 and R1 was only present in KI allele with a length of 268 bp. The PCR condition for each cycle was the following: (1) 95°C −5min; (2) 95°C −30sec, 62°C −30sec, 72°C −35 seconds with 35 cycles; (3) 72°C −10 minutes.
The proteolipid protein 1(Plp1)-CreER+ mouse strain (Jax#: 005975) came from the Jackson laboratory. The Ai47 Cre reporter mouse, Rosa26-CAG-LSL-3xEGFP, was requested from Dr Zilong Qiu from the Institute of Neuroscience (ION), CAS. The "3xEGFP" refers to three DNA elements coding for different EGFPs: Emerald-GFP (EmGFP), TagGFP2, and humanized Renilla-GFP (hrGFP). These were connected via the 2A method, as described in one previous study. 18 All mice were maintained according to guidelines of the IACUC of Institute of Neuroscience (ION), Chinese Academy of Sciences. Mice of either sex were used for the experiments.
| Sample processing, histology, and immunofluorescence
All mice were given tamoxifen (T5648, Sigma) dissolved in corn oil (C8267, Sigma) at P0 and P1, or at P14 and P15, with a 24 hours interval. Tamoxifen dosage was 3mg/40g of mouse body weight. Mice were heart-perfused with 1xPBS followed by a perfusion with fresh 4% PFA. Inner ear tissues were dissected out and further fixed in 4% PFA at 4°C overnight, followed by 1xPBS wash, repeated three times and decalcified with EDTA. After that, they were soaked in 30% sucrose at 4°C overnight and embedded in OCT for cryo-sections with 14μm thickness. Inner ear samples which contained all three cochlear turns were chosen for immunostaining; this aided in determining the exact location of the SGNs when we analyzed samples.
The following primary antibodies were used: anti-GFP (chicken, 1:1000, ab13970, abcam), anti-Tuj1 (mouse, 1:500, 801201, BioLegend), anti-Prox1 (rabbit, 1:500, AB5475, Millipore), Anti-Map2 (rabbit, 1:400, M3696, Sigma), Anti-Mbp (mouse, 1:200, ab62631, abcam), anti-Mafb (rabbit, 1:300, HPA005653, Sigma), anti-Gata3 (goat, 1:200, AF2605, R&D systems), anti-Sox10 (goat, 1:200, sc-17342, Santa Cruz Biotechnology), anti-HA (rat, 1:200, 11867423001, Sigma), anti-Neurod1 (goat, 1:200, sc-1084, Santa Cruz Biotechnology). All secondary antibodies were purchased either from Thermo Scientific or Jackon ImmunoResearch Laboratory. Finally, samples were counter stained with Hoechst33342 (1:1000, 62249, Thermo Scientific) solution in 1xPBS to visualize nuclei and were mounted with Prolong gold anti-fade mounting medium (P36930, Thermo Scientific). All images were captured using Nikon NiE-A1 plus or Nikon C2 confocal microscope, and analyzed using Image J. For detailed inner ear histology protocol, please refer to our previous study. 19 
| Quantification and statistical analysis of the new SGN populations
Inner ear cryo-section slices with all three cochlear turns were chosen for analysis; we focused on the middle or apical SGN regions where more new SGNs were observed. F I G U R E 1 Generation of Rosa26-LSL-Ngn1-Neurod1/+ mouse strain. A-C, Illustration of wild-type Rosa26 locus (A), gene targeting vector (B), and Rosa26 locus post gene targeting (C). Ngn1 was tagged with 3xHA and Neurod1 with 3xFlag at their C-terminus. Ngn1 and Neurod1 cannot be expressed unless the stop fragment is removed by Cre. D-E, Southern Blot analysis using tail genome DNA extracted from F1 mice with 5′-probe outside of 5′-arm (D) and internal probe within WPRE sequences (E). F, PCR genotyping on tail DNA was performed using three mixed primers F1, R1, and R2. The size of knock-in (KI) allele was 268 bp, and wild type (+) was 469 bp. KI/ KI: homozygous, KI/+: heterozygous, +/+: wild type Approximately, six good slices with all three cochlear turns were obtained per mouse. The field of view of the confocal microscope (60× objective lens) was sufficiently large to cover most of the SGN area per turn. The samples were scanned in z-stack mode every 0.6 μm. For each mouse (either left or right ears were analyzed), the total number of EGFP+ cells was normalized to total number of SGN regions (5 ~ 8) scanned to calculate an average number of EGFP+ cells (regardless of cell fate). Similar approaches were used to quantify the percentage of new SGNs (using different neuronal markers) among the EGFP+ cells. Note that we did observe EGFP+ new SGNs in SGN regions of basal turn but with a lower frequency. All cell numbers were presented as Mean ± SEM. Cell counts were compared by a one-way ANOVA, followed by a Student's t test with a Bonferroni correction. GraphPad Prism 6.0 was used for all statistical analyses.
| Manual cell picking, qPCR and RNA-
Seq library construction
Manual cell picking was used for all three different mouse models. For wild-type glial cells, Plp1-CreER+；Rosa26-CAG-LSL-3xEGFP/+ mice were used. For new SGNs, both Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/+ and Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/ Rosa26-LSL-Ngn1-Neurod1 were used. All models were given tamoxifen at P0 and P1, and samples were dissected and digested at P16. Detailed cell picking protocol can be found in our previous study. 2 Approximately 25 ~ 30 cells were picked per replicate and RNA was extracted with PicoPure RNA Isolation Kit (Thermo Scientific, Cat# KIT0204) and cDNA was obtained with Ovation RNA-Seq system V2 (Nugen, Cat# 7102-32). qPCR analysis was performed using the SYBRGreen JumpStart Taq Ready-Mix Kit (Sigma, S4438) on Roche 480II qPCR machine. All primers for each gene were pretested using standard curve analysis; the amplification efficiency was found to be between 0.9 and 1.1. The detailed primer sequences are listed in Table S1 . The cDNAs of samples passing qPCR quality control were fragmented using focused-ultrasonicator (Covaris, ME220 model). The final sequencing libraries were constructed via Ovation Rapid DR multiplex system (Nugen, Cat# 0319-32) and sequenced by Illumina Hiseq4000 platform. The raw data of RNA-Seq were deposited in NCBI SRA database with accession code: PRJNA544182.
| Transcriptome analysis between different cell populations
An average of 80 million reads were obtained per replicate. FastQC (v0.11.3) and Trimmomatic (v0.36) were used for quality control. 20 About 87% of reads were mapped to the mouse reference genome (GRCm38) with high quality, using STAR (v2.5.2b) with default parameters. 21 RSEM (v1.2.21) software was used to estimate the gene expression levels on the alignment file with default parameters. Gene abundances were presented in Transcript Per Million (TPM). 22 Differentially expressed genes were calculated based on raw counts using the HTSeq (v0.10.0) software. 23 Besides our control wild-type glial cells (ID: #1, #2, and #3), new SGNs (ID: #4, #5, and #6) from experimental group-1 and new SGNs (ID: #7, #8, and #9) from experimental group-2, we also downloaded data from one previous SGN single-cell RNA-sequencing data. 4 This data were also generated by manual picking making it potentially comparable to our data. We re-analyzed the data and divided cells into four clusters based on results of t-SNE: Type I-A, Type I-B, Type I-C, and Type II ( Figure 10 ), consistent with the original report of SGN subtypes. 4 We chose four samples, which were #372, #373, #365, and #452, to represent Type I-A, Type I-B, Type I-C, and Type II, respectively. These were distributed in the middle of their own clusters and should best represent global gene expression profiles of each cell type ( Figure 10 ).
Initial cluster analysis suggested that new SGNs resembled Type I SGNs more than Type II. Therefore, we compared transcriptomes among our control wild-type glial cells (ID: #1, #2, and #3) and wild-type Type I SGNs (#372, #373, and #365), and chose the genes that showed significant differences between wild-type glial cells and SGNs (1927 genes). Next, we performed PCA analysis on these 1927 genes and looked at where the new SGNs from experimental group 1 and 2 were relative to the control cells. Functional enrichment analysis was performed by Metascape. 24 
| RESULTS
| Generating a new mouse line with inducible expression of Ngn1 and Neurod1
Transcription factors are widely used for cellular reprogramming. 25 Neurog1 (also known as Ngn1) and Neurod1 are b-HLH transcription factors that are necessary for SGN development. 26, 27 In addition, Neurod1 is known to reprogram chromatin, induce neuronal gene expression, and is sufficient to successfully reprogram in vitro cochlear glial cells into SGNs which express neuronal markers, Tuj1, Map2, and Prox1. 15, 28 We set out to induce ectopic Ngn1 and Neurod1 expression in neonatal cochlear glial cells in vivo via the Cre/ Loxp-mediated genetic approach. 29 We firstly constructed a new Cre-mediated conditional knock-in mouse strain, Rosa26-CAG-Loxp-stop-Loxp-Neurog1*3xHA-P2A-Neurod1*3xFlag-T2A-EGFP, which for short we called Rosa26-LSL-Ngn1-Neurod1 ( Figure  1A -C). Southern blot analysis confirmed that there was no random insertion ( Figure 1D ,E). By tail DNA PCR genotyping, wild type, heterozygous, and homozygous mice were easily identified ( Figure 1F ). If a Rosa26-LSL-Ngn1-Neurod1 mouse is crossed with the glial cell specific Plp1-CreER mouse (to be described in details below), the double positive offspring would express polycistronic mRNA containing Ngn1 (tagged with 3xHA), Neurod1 (tagged with 3xFlag) and EGFP in glial cells upon exposure to tamoxifen (Figure 2A ). Furthermore, fused protein (Ngn1-Neurod1-EGFP) was translated first, and individual protein was generated via 2A oligopeptide-mediated cleavage. 30 In addition, via this design, co-expression of Ngn1, Neurod1, and EGFP were guaranteed, which was confirmed by co-staining of EGFP with HA tag antibody ( Figure 2B -D'') or Neurod1 antibody ( Figure 2E -G''). We intended to stain Neurod1 with Flag antibody but failed to obtain good immunostaining signal. The nuclear expression of HA (Ngn1) and Neurod1 in EGFP+ cells occurred in a heterogeneous pattern (white arrows in Figure 2C -D'',F-G''). Surprisely, we also detected Neurod1+/EGFP− cells (yellow arrows in Figure 2E -G'') in both control and experimental groups, however, the Neurod1 distribution is membranous. It is possible that the Neurod1 antibody is not very specific or other cell types (i.e. blood vessel cells) did express Neurod1 in postnatal cochleae. Nonetheless, the permanent EGFP expression permitted lineage tracing and cell fate conversion analysis at a single-cell resolution as described below.
| Ectopic Ngn1 and Neurod1 can rapidly reprogram neonatal cochlear glial cells into SGNs within 6 days
To specifically induce ectopic Ngn1 and Neurod1 in neonatal cochlear glial cells, we used Plp1-CreER as the Cre driver 
. EGFP+ cells expressed Ngn1 in both experimental groups (white arrows in C-D'') but not in the control group. E-G'', Co-staining of EGFP and Neurod1 in the three groups. Again, EGFP+ cells with nuclear expression of Neurod1 were observed in experimental group-1 (white arrows in F-F'') and experimental group-2 (white arrows in G-G''), but not in control group (E-E''). Note that Neurod1 signal was detected in EGFP− cells in all three groups (yellow arrows in E-G''). The identity of these cells remains unclear. Scale bars: 20 μm
Tamoxifen at P0/P1 P6 as it can label glial cells in postnatal cochlea, as reported in previous studies. 31, 32 We also independently characterized Plp1-CreER+; Rosa26-CAG-LSL-3xEGFP (Ai47)/+ mice (control group) that were given tamoxifen at postnatal day 0 (P0) and P1, and analyzed at P6. Cre-mediated EGFP expression overlapped with the glial marker Sox10 but not the neuronal marker Tuj1 (white arrows in Figure 3A -A'''). This confirmed the glial specific induction of Cre activity by Plp1-CreER+. Neither EGFP+/HA (Ngn1) + nor EGFP+/ Neurod1+ cells were observed in control group ( Figure  2B -B'',E-E''). EGFP+ cells in control group were wild-type glial cells, as demonstrated by overlapping Sox10 expression. In contrast to the control group, EGFP+/Tuj1+ cells were present in abundance in the two different experimental groups that were also give tamoxifen at P0 and P1, and analyzed at P6 (white arrows in Figure 3B -C'''). The first group was Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/+ (one copy of Ngn1 and Neurod1) and was called for short experimental F I G U R E 3 Glia-derived new SGNs turn on Tuj1 and Prox1 expression and reduce the glial marker Sox10 expression. A-C''', Triple staining of EGFP, Tuj1, and Sox10. Majority of EGFP+ cells expressed Sox10 but not Tuj1, confirming that they were indeed glial cells (white arrows in A-A'''). Note that a few EGFP+ glia cells expressed low or undetectable amounts of Sox10 (white stars in A-A'''), illustrating the fact that glial cells are heterogeneous. In contrast, EGFP+/Tuj1+ cells were observed in experimental group-1 and 2 (white arrows in B-C'''). These cells were defined as glial cells-derived new SGNs and also decreased glial marker Sox10 expression. Yellow arrows in (B-C''') pointed to EGFP+/Sox10+ cells which maintained glial phenotype and did not express Tuj1. D-F''', Triple staining of EGFP, Tuj1, and Prox1. Neither Tuj1 nor Prox1 was expressed in EGFP+ glial cells in the control (white arrows in D-D'''). group-1. The second group was Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/Rosa26-LSL-Ngn1-Neurod1 (two copies of Ngn1 and Neurod1) and was named as experimental group-2. This demonstrated that upon Cre-mediated recombination, glial cells expressed EGFP, Ngn1, and Neurod1. Some of these cells also started expressing neuronal markers Tuj1; these were defined as glial lineage-derived new SGNs (new SGNs for short). Promisingly, most, if not all, of these new SGNs did not express Sox10 (white arrows in Figure 3B -C'''). We also observed EGFP+ cells that maintained Sox10 and did not express Tuj1 (yellow arrows in Figure 3B -C''').
These cells, which should be different from wild-type glial cells due to the induced Ngn1 and Neurod1 expression, were still defined as glial cells in our current study. Together, this suggested that Sox10 expression was repressed when neonatal glial cells were converted into SGNs. Additional triple staining of EGFP, Tuj1, and Prox1 was performed. In control group, EGFP+ cells expressed neither Tuj1 nor Prox1 (white arrows in Figure 3D -D'''). However, EGFP+/Tuj1+/Prox1+ cells were observed in the two experimental groups (white arrows in Figure 3E -F'''). Intriguingly, we also captured cells that expressed EGFP and Tuj1 but not Prox1 (yellow arrows in Figure 3E -F'''). We did not observe cells that expressed EGFP and Prox1, but not Tuj1. This highlighted the variability in induction of neuronal gene expression in glia. Note that EGFP+ cells would be defined as new SGNs in our study, as long as they turned on one of the typical SGN markers. Because new SGNs were more frequently found in middle or apical turns at all ages (P6, P16 and P42) analyzed, we focused on them for the rest of the study.
Every tissue slice (~14 μm thickness) contained EGFP+ cells in the SGN region of the middle or apical cochlear turns. An average of 183.4 ± 8.4 EGFP+ cells were found in experimental group-2 at P6 (n = 3, mouse numbers); a smaller number was identified in experimental group-1 at P6, 135.0 ± 9.6 (n = 3, mouse numbers) ( Figure 3G ). Similarly, 61.9% ± 3.2% of the EGFP+ cells expressed Tuj1+ in experimental group-2, as compared to the lower 48.6% ± 1.8% found in experimental group-1 ( Figure 3H ). This suggested that two copies of Ngn1 and Neurod1 reprogrammed neonatal glial cells more efficiently into new SGNs than single copy. About 16.1% ± 3.6%, and 18.6% ± 2.8% of EGFP+ cells expressed Prox1 in experimental group-1 and group-2 at P6, respectively, ( Figure 3H ) and we did not see a statistically significant difference. Note that the cell body size of new SGNs were generally smaller than the surrounding wild-type SGNs (Prox1+/EGFP− or Tuj1+/EGFP−) in each group. We next wanted to assess how trans-differentiation of neonatal glia into new SGNs would progress as the animal aged, specifically focusing on the reprogramming efficiency and quality (i.e. the extent to which new SGNs resembled wild-type SGNs, and cell body morphology).
| New SGNs with large cell body were more frequently observed at P16
We analyzed cochlear samples from control and two experimental group mice that were given tamoxifen at P0/P1, and analyzed at P16 (Figure 4 ). Besides co-staining of EGFP with Tuj1 or Prox1 as described in Figure 3 , we performed costaining of EGFP and another neuronal marker Map2. In the control group, EGFP+ cells did not express Map2 (yellow arrows in Figure 4A -A''). In contrast, EGFP+/Map2+ cells were frequently observed in the two experimental groups (white arrows in Figure 4B -B'',C-C''). Again those cells were defined as new SGNs. A greater percentage of new SGNs with large and round nuclei (white arrows in Figure  4B -C'') were found at P16 than P6. More specifically, we found that EGFP+/Map2+ new SGNs always had larger cell bodies than EGFP+ cells that did not express Map2 and maintained as glial cells (compare white and yellow arrows in Figure 4B -C''). It suggested that, although those new SGNs were able to turn on Tuj1 or Prox1 as early as on P6 (Figure 3 ), those new SGNs may take ~16 days to be more differentiated and display large cell bodies.
Quantification analysis from multiple sections from three mice (either left or right ears) showed that 17.9 ± 0.7 (n = 3, mouse numbers) EGFP+ cells were found in experimental group-1 at P16, which was significantly smaller than the 31.6 ± 1.0 (n = 3, mouse numbers) found in experimental group-2 at P16 ( Figure 4D ). For each experimental group, the numbers of EGFP+ cells at P16 were lower than that found at P6 (compare Figures 3G and 4D ), indicating that cell death likely occurred among EGFP+ cells between P6 and P16. Nevertheless, 54.1% ± 8.8% and 58.9% ± 8.4% of those EGFP+ cells were Tuj1+ (new SGNs) in experimental group-1 and 2, respectively; no significant difference was observed between two experimental groups ( Figure 4E ). 32.5% ± 5.6% of EGFP+ cells were Prox1+ in experimental group-1, which was slightly less than the 46.8% ± 2.0% found in experimental group-2 ( Figure 4E ). Lastly, 37.9% ± 6.8% and 51.7% ± 10.7% of EGFP+ cells were Map2+ in experimental group-1 and 2, respectively, and no significant difference was found ( Figure 4E ). Together, compared with new SGNs at P6, new SGNs displayed larger cell bodies and looked morphologically more like wild-type SGNs at P16. We picked new SGNs at P16 and performed RNA-Sequencing (RNA-Seq) analysis, as described below.
In addition, we determined whether fibers of those new SGNs were myelinated by the remaining glial cells (either EGFP+ or EGFP−). Myelin basic protein (Mbp) is one of three major myelin proteins and expressed in mouse SGN region. 33, 34 Triple staining of EGFP, Mbp, and Prox1 showed that, similar to SGNs in control mice at P6 (arrows in Figure  S1A -A''') and at P16 (arrows in Figure S1C -C'''), the new SGNs (EGFP+/Prox1+) in experimental group-2 mice were circled by the Mbp+ myelin sheath at P6 (arrows in Figure  S1B -B''') and at P16 (arrows in Figure S1D -D'''). It supported that new SGNs were myelinated.
| New SGNs are still viable at P42
In addition to P6 and P16, we also analyzed new SGNs at P42. We analyzed cochlear samples dissected from mice at P42 that were given tamoxifen at P0/P1 ( Figure 5 ). Similar to what we observed at P6 and P16, no EGFP+ cells expressed neuronal marker Map2 in the control group (yellow arrows in Figure 5A -A''). In contrast, new SGNs that co-expressed EGFP and Map2 were observed in experimental-1 (white arrows in Figure 5B -B'') and experimental-2 group (white arrows in Figure 5C -C''). Note that we observed multiple new SGNs with cell size and rounded morphology similar to that of the neighboring wild-type SGNs (Map2+/EGFP−) in experimental-2 group (white arrows in Figure 5C -C''). Again, EGFP+ cells, which did not express Map2, maintained as glial cell fate and displayed smaller cell bodies (yellow arrows in Figure 5B -C''). Quantitative analysis revealed that there were on average 20.9 ± 5.7 (n = 3, mouse numbers) EGFP+ cells in experimental group-1, and 18.3 ± 1.6 (n = 3, mouse numbers) EGFP+ cells in experimental group-2. No significant difference was present between the two experimental groups. Similar to P16, the total numbers of EGFP+ cells in both experimental groups were much less than those at P6 ( Figure 5D ). A significant difference was also observed when comparing the total number of EGFP+ cells in experimental group-2 at P16 and P42 ( Figure 5D ).
We next quantified the percentage of new SGNs among EGFP+ cells using different neuronal markers. We found that 6.7% ± 1.9% were Tuj1+ in experimental group-1, which was significantly less than 37.2% ± 6.0% in experimental group-2 ( Figure 5E ). Approximately, 12.7% ± 4.0% and 16.2% ± 6.0% were Prox1+ in experimental group-1 and 2, respectively, and there was no significant difference ( Figure 5E ). We found that 2.8% ± 0.8% were Map2+ in experimental group-1, which was significantly less than the 35.7% ± 7.9% found in experimental group-2 ( Figure 5E ). Together, this showed that new SGNs could survive at least until P42. Consistent with the observation at P6 ( Figure 3H ) and P16 ( Figure 4E ), two copies of Ngn1 and Neurod1 in experimental group-2 generally displayed a higher percentage of new SGNs than the single copy in experimental group-1 ( Figure 5E ). We further confirmed this Ngn1 and Neurod1 dosage-dependent effect on reprogramming efficiency using transcriptomic assays in the sections below. 
| A small fraction of new SGNs express Mafb with cell size and morphology comparable to that of wild-type SGNs
We next aimed to determine whether the new SGNs which had larger and rounder cell bodies also expressed critical genes for SGN differentiation and function, such as Mafb. Mafb is required for SGN normal development; indeed, SGNs fail to form the normal ribbon synapses in Mafb -/mice. 35 In control group, EGFP+/Tuj1+/Mafb+ cells were never observed (white arrows in Figure 6A -A''' and 7A-A'''). Although most of the EGFP+/Tuj1+ new SGNs failed to express Mafb (white arrows in Figure 6B -C'''), a few new SGNs did express Mafb (white arrows in Figure 7B -C'''). Quantification analysis showed that 5.70% ± 0.73% (n = 3, mouse numbers) and 4.22% ± 0.67% (n = 3, mouse numbers) of the new SGNs expressed Mafb in experimental group-1 and experimental group-2, respectively, and no statistically significant difference were observed at P16 ( Figure 7D ). As previously mentioned, the nuclei size of these EGFP+/ Mafb+ cells was consistently comparable to neighboring wild-type SGNs. The presence of EGFP+/Mafb+ new SGNs was also confirmed by our transcriptomic analysis; see below for details.
| Transcriptome analysis confirms the heterogeneous nature of new SGNs
Our immunostaining assays described above demonstrated the cell fate conversion from neonatal glial cells into SGNs via ectopic Ngn1 and Neurod1. We next wanted to compare the transcriptome of the different cell populations. To this end, we performed RNA-Seq on glial cells from control and new SGNs from two experimental groups. We manually picked EGFP+ cells from each group and pooled them together for per replicate at P16 ( Figure 8A ). We pooled cells and used bulk RNA-Seq, instead of single-cell RNA-Seq, because we aimed to cover more genes. Our qPCR analysis showed that Ngn1, Neurod1, and Tuj1 were significantly enriched in cells from experimental groups, relative to those from control group ( Figure 8B-D) . In addition, Ngn1 and Tuj1 were much more highly expressed in experimental group-2 than that in experimental group-1. No significant differences were observed between two experimental groups with respect to Neurod1. We speculated that, besides the Neurod1 expressed from the Rosa26 loci, ectopic Ngn1 may turn on endogenous Neurod1. The initial qPCR analysis guaranteed the quality of cells that we manually picked. 
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(red arrows in Figure 9A ). To assess whether this was a chance detection or real signal, we further checked the expression of Gata3 (Yu et al, 2013 ), a gene that is known to positively regulate Mafb, in samples #4 and #9. Gata3 was indeed also detected in samples #4 and #9 with a TPM value of 4.75 and 4.25, respectively ( Figure 9B ). Meanwhile, Gata3 displayed no expression in all other samples ( Figure 9B ). Lastly, we also captured EGFP+ new SGNs that co-expressed Mafb and Gata3 at P16 ( Figure 9C -C''').
Although Mafb and Gata3 were only significantly enriched in new SGNs of samples #4 and #9, Tuj1 (Tubb3), Prox1, and Map2 were, at different degrees, enriched in all the six samples (#4, #5, #6 and #7, #8, #9) of two experimental groups (green arrows in Figure 9D ). It demonstrated that new SGNs were present in all the samples of experimental groups. In addition, we checked other SGN genes such as Calb2, Pou4f1, Lypd1, Slc17a6, Slc17a7, and Pvalb, which have recently been reported in different SGN single-cell RNA-Seq studies. [3] [4] [5] Samples #4 and #9 showed enhanced expression of all of these SGN genes compared to other samples (red arrows in Figure 9D ). In parallel to this, there was a sharp drop in the expression of glia-related genes such as Scn7a in samples #4 and #9, as compared to the levels found in the control glia cells (#1, #2, and #3). Samples #5, #6, #7, and #8, in which Mafb and Gata3 expression was low or undetectable, expressed intermediate levels of Scn7a. Taken together, the RNA-Seq analysis confirmed that EGFP+/ Mafb+ new SGNs were better reprogrammed into SGN fate than those lacking Mafb expression. However, such cells were rare and only captured in two (#4 and #9) out of six samples from two experimental groups.
| Mafb+/Gata3+ new SGNs resemble wild-type I SGNs
We next specifically explored whether new SGNs from samples #4 and #9 resembled type I or type II SGNs. We downloaded a single-cell RNA-Seq dataset from a previous wild-type SGN single-cell study covering both type I and II SGNs, which was also performed via manual picking approach, and could serve as reference to score our new SGNs. 4 We were also able to divide the SGN single cells into four clusters (or cell types): Type I-A, Type I-B, Type I-C, and Type II ( Figure 10A ). One cell, which was located in the middle of each cluster, was picked to represent each cell type: Type I-A (#372), Type I-B (#373), Type I-C (#365), and Type II (#452). Those sample IDs were used according to the original report. 4 Hierarchical clustering analysis (HCA) showed that new SGNs from #4 and #9 resembled type I EGFP+ cells from control and two experimental groups were picked. Per replicate, ~30 EGFP+ cells were collected in each group. B-D, qPCR analysis of three genes: Ngn1 (B), Neurod1 (C) and Tuj1 (D). y-axis: fold change of mRNA in control, experimental group-1 and 2. The data were normalized to set the control value to be 1 for each gene. Compared to control, all genes were significantly more expressed in experimental groups. In addition, Ngn1 and Tuj1 also showed significant difference between experimental group-1 and 2. *P < .05 SGNs more than type II SGNs, as they were closer to each other ( Figure 10B ). However, detailed computational analysis revealed that expression levels of 575 genes were significantly different (P < .05) among best reprogrammed new SGNs (#4 and #9) and type I SGNs (File S1). Those top differently expressed genes (i.e. Nol11 and Rrm2b), and genes not significantly different (i.e. Map7 and Mdp1) were presented as examples in Figure 10C . It suggested that, although new SGNs from #4 and #9 were more similar to type I SGNs, additional factors are needed to further minimize their transcriptomic difference.
| Transcriptome analysis also supports that two copies of Ngn1 and Neurod1 results in better reprogramming of glial cells to SGNs than a single copy
To confirm the dosage-dependent effect of Ngn1 and Neurod1 on neonatal glial cells to SGN cell fate conversion, as supported by previous immunostaining assays (Figures 3-5 ), we further compared the transcriptome profiles between new SGNs from the two experimental groups and control glial cells. In total 1927 genes showed significantly differential expression among control glial cells (#1, #2, and #3) and three (#372, #373, and #365) Type I wild-type single SGNs. As illustrated in Figure 11A , principal component analysis (PCA) via those 1927 genes clearly divided cells into four clusters: control glial cells, type II SGNs, new SGNs, and Type I SGNs.
Apparently, new SGNs were closer to Type I SGNs than control glial cells ( Figure 11A ). Next, transcriptomic comparison was performed between control glial cells and new SGNs of experimental group-1 (#4, #5, #6), and experimental group-2 (#7, #8, #9), respectively. There were 87 upregulated, and 540 downregulated genes in SGNs of experimental group-1 ( Figure 11B) , and the full list of those 627 genes were summarized in File S2. In contrast, 368 genes were upregulated, and 867 were downregulated in new SGNs of experimental group-2 ( Figure 11C) , and the full list of those 1235 genes were summarized in File S3. Mafb EGFP We additionally performed gene functional enrichment analysis on these differentially expressed genes and found that the 368 upregulated genes in the new SGNs of experimental group-2 were significantly enriched in neuron differentiation and neurotransmitter secretion pathway (red arrows in Figure 11C') . Consistently, Schwann cell differentiation genes were downregulated in new SGNs of both experimental group-1 and experimental group-2 (green arrows in Figure 11B '' and C''). Moreover, they were more significantly downregulated in experimental group-2. Together, these results supported that two copies of Ngn1 and Neurod1 overall could better reprogram glial cells into SGNs and activate more neuron differentiation genes, and simultaneously repress Schwann cell differentiation genes.
| Juvenile glial cells were insensitive to ectopic Ngn1 and Neurod1
Next we determined whether juvenile glial cells at 2 weeks old of age are responsive to ectopic Ngn1 and Neurod1. Plp1-CreER+; Rosa26-CAG-LSL-3xEGFP (Ai47)/+ (control) and Plp1-CreER+;
Rosa26-LSL-Ngn1-Neurod1/Rosa26-LSL-Ngn1-Neurod1 (experimental group-2) mice were given tamoxifen at P14 and P15, and analyzed at P25. Numerous EGFP+ cells expressed Sox10 but not Tuj1 in control mice (white arrows in Figure 12A -A'''), confirming that they were glial cells. Unfortunately, we no longer observed the EGFP+/ Tuj1+ cells in experimental group-2 mice. It supported that juvenile glial cells, different from neonatal glial cells, were insensitive to ectopic Ngn1 and Neurod1. Consistently, those EGFP+ cells maintained glial marker Sox10 (white arrows in Figure 12B -B'''). Such a declined reprogramming efficiency was also reported in Ascl1-mediated cell fate conversion from Müller glia to neurons in mouse retina after P16. 36 
| Neonatal cochlear supporting cells are normal with ectopic Ngn1 and Neurod1
Our previous study showed that cochlear SCs, primarily the inner phalangeal cells (IPhs) also could be targeted by the Plp1-CreER+ strain. 37 Therefore, we determined whether ectopic Ngn1 and Neurod1 would also affect cell fate of IPhs. Plp1-CreER+; Rosa26-CAG-LSL-3xEGFP (Ai47)/+ (control) and Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/+ (experimental group-1) mice were given tamoxifen at P0 Rbm25 
(C)
and P1, and analyzed at P6. In both control mice ( Figure  13A -B''') and experimental group-1 mice ( Figure 13C -D'''), EGFP+ IPhs did not express Map2 or Tuj1. Instead, they expressed SC marker Sox2 (arrows in Figure 13 ). EGFP+ IPhs were also Sox2+ when samples were analyzed at P16. Consistently, HCs were also normal in both groups. We additionally analyzed Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/Rosa26-LSL-Ngn1-Neurod1 (experimental group-2) mice and EGFP+ IPhs were Sox2+, too. Together, it suggested that cell fate of IPhs were still maintained even with ectopic Ngn1 and Neurod1 expression.
| DISCUSSION
In summary, our data showed that conditional induction of ectopic 
| Cochlear neonatal glia cells are plastic and can be reprogrammed into SGNs in situ
Previous studies showed that cochlear glia cells were plastic and could be converted into SGNs in vitro. 15 Our current study further demonstrated plasticity of neonatal glial cells in vivo. Our data supported that neonatal glial cells distributed in middle and apical cochlear turns were more plastic than those in basal turn (data not shown). Although cochlear glial cells has not been well studied yet, it is known that they can proliferate after damage. 40 This proliferative capacity may have advantages and it may help glial cells to repopulate, if some glial cells were converted to SGNs. We also noticed that glial cells were heterogeneous in many aspects, as glial cells at least have two subtypes: Schwann cells and Satellite cells. SGN axons are myelinated by Schwann cells, and SGN cell bodies are wrapped by satellite cells. 31, 32 Intriguingly, in control Plp1-CreER+; Rosa26-CAG-LSL-3xEGFP (Ai47)/+ mice, majority of EGFP+ cells expressed glial marker Sox10, but we did observe a few EGFP+ cells with low or undetectable Sox10 (stars in Figure  3A -A'''), which suggested that glial cells were heterogeneous regarding Sox10 expression. In both experimental groups, EGFP+/Tuj1+ new SGNs diminished Sox10 expression ( Figure 3B-C''') . Therefore, there were at least two explanations: one is that new SGNs decreased Sox10 during the reprogramming process; the other is that some new SGNs derived from neonatal glial cells that originally expressed low or undetectable Sox10.
| Multiple factors contribute to the heterogeneities of new SGNs
Our data clearly showed that new SGNs were heterogeneous ( Figures 3H, 4E and 5E ), suggesting that Tuj1 might be one of the earliest neuronal genes that new SGNs expressed. For instance, we observed new SGNs that expressed Tuj1 but not Prox1 (yellow arrows in Figure 3E -F'''). In addition, while the majority of new SGNs did not express Mafb ( Figure 6 ), a small population of new SGNs expressed Mafb highly (Figure 7) . Interestingly, Gata3 was also expressed in those EGFP/+Mafb+ new SGNs with large and rounded cell bodies (Figure 9 ), consistent with the requirement of Gata3-Mafb cascade during normal SGN development. 35 We speculated that once co-expression of Mafb and Gata3 was established in SGNs, this would act as a trigger inducing the expression of many other SGN genes, decreasing the expression of glial genes and leading the cells to display large rounded cell bodies akin to wild-type SGNs, as shown in Figure 9 . Note that in this context Gata3 and Mafb should not be regarded as type II specific SGN marker, especially in those new SGNs, as these genes are expressed in both type I and II SGNs. 35, 41 Similarly, Pou4f1 is expressed in all SGNs at early embryonic ages but restricted to a subset of type I SGNs at adult ages. 38, 39, 42 What could account for the heterogeneities of new SGNs? We provided two potential explanations. The first is that the heterogeneities are correlated with the original heterogeneous glial cells. It is possible that a small subset population of neonatal glial cells respond much better to ectopic Ngn1 and Neurod1 and are reprogrammed to SGN state with Mafb and Gata3 expression. The second is that reprogramming process itself is a stochastic process and there are various barriers at different steps, as also suggested by a recent Atoh1-mediated reprogramming of adult mouse utricle SCs into HCs. 43 We currently do not understand the mechanisms underlying the conversion of glial cells into SGN fate mediated by Ngn1 and Neurod1, nor how Ngn1 and Neurod1 regulate cell fate specification and differentiation in wild-type SGNs. Recently, it was reported that Ngn1 regulates CDK2 to promote proliferation in otic progenitors. 44 Although we believe that the Mafb+ new SGNs might be able to partially function as wild-type SGNs, we cannot yet confirm this due to the current inability to identify Mafb+ new SGNs in alive tissues. To overcome this we plan on generating a Mafb-P2A-tdtomato/+ knock-in mice to enable precise identification of the cells, allowing us to assess the electrophysiological properties of the rare Mafb+ new SGNs (EGFP+/tdtomato+) via patch-clamp recording in Plp1-CreER+; Rosa26-LSL-Ngn1-Neurod1/Rosa26-LSL-Ngn1-Neurod1; Mafb-P2A-tdtomato/+ mice. shows higher reprogramming efficiency than one copy
Our quantification of results from the co-staining of EGFP and neuronal markers Tuj1, Prox1, and Map2 supported that two copies of Ngn1 and Neurog1 in experimental group-2 induced a higher reprogramming efficiency than a single copy of Ngn1 and Neurog1 in experimental group-1 (Figures 3H,  4E , and 5E). Consistently, our PCA analysis also suggested that the distance (or difference) between new SGNs from experimental group-2 and glial cells was larger than that between new SGNs from experimental group-1 and glial cells. Nonetheless, our data also showed that new SGNs from sample #4 (experimental group-1) and sample #9 (experimental group-2) were best reprogrammed. What could explain the reason that new SGNs from samples #7 and #8 (experimental group-2) were less reprogrammed than those in sample #4? We speculated that this seeming conflict was caused by the cell picking approach we used. EGFP+ cells were wildtype glial cells in control group, however, EGFP+ cells were either new SGNs or cells that maintained glial cell fates in the two experimental groups, as described above. We currently do not have the genetic model to exclusively select new SGNs. Instead, we tried our best to pick the EGFP+ cells with bigger and rounder nuclei, which would more likely be new SGNs according to our previous analysis at P16 ( Figure  4 ). Glial genes Sox10 and Plp1 are highly expressed in glial cells, however, they did not show a significant difference among control and all experimental groups. Therefore, we proposed that our so-called new SGNs from two experimental groups, which were manually picked based on morphology and EGFP fluorescence, were mixed with a few glial cells. It is possible that the new SGNs from sample #4 (experimental group-1) had the least contaminations of EGFP+ glial cells, making new SGNs from sample #4 seem better reprogrammed than new SGNs from sample #7 and #8 (experimental group-2) that unfortunately had more contaminations of EGFP+ glial cells. Such glial contamination might reduce the sensitivity of our transcriptomic analysis, preventing us from thoroughly appreciating the dosage-dependent reprogramming effects of Ngn1 and Neurod1. Last, it is possible that if we use transgenic, instead of knock-in approach, we might obtain multiple insertions of Ngn1 and Neurod1 transgene that would lead to higher Ngn1 and Neurod1 expression and better reprogramming efficiency.
| Regenerating SGNs in a mouse model with prior degeneration
The primary aim of our current pilot study was to demonstrate the plasticity of glial cells which, upon ectopic Ngn1
and Neurod1, can be reprogrammed into SGNs. Note that our current model did not include any cochlear SGN degeneration prior to turning on Ngn1 and Neurod1 at P0/P1. It remains to be seen whether prior SGN death might promote Ngn1 and Neurod1-mediated glial cell to SGN fate conversion or increase the numbers of Mafb+ new SGNs. Ouabain, a potent inhibitor of Na + /K + -ATPase pump, can trigger degeneration of SGNs at adult mammalian cochlea. 45, 46 We are not aware of any studies using ouabain in neonatal cochlea in vivo. If ouabain is toxic to neonatal mice, we plan on generating a genetic mouse model such as Lypd1-P2A-DTR/+ to conditionally induce cell death of Lypd1+ SGNs, as SGN subtypes expressing Lypd1 are more vulnerable to degenerate in aged mice. 4 Diphtheria toxin (DT) treatment will trigger binding of DT with Diphtheria toxin receptor (DTR) and turn on a signaling cascade leading to cell death. This would be a promising model to mimic human aging-related SGN degeneration. Based on this model, we could further test whether combinational induction of Ngn1, Neurod1, and other factors (i.e. Mafb and Gata3) in glial cells will regenerate functional SGNs.
